DR. HOWARD YUAN-HAO CHANG, M.D., PH.D.
Dermatology at Blake Wilbur, Palo Alto, CA
License number
California A76256
Category
Osteopathic Medicine
Type
Dermatology
Address
Address
900 Blake Wilbur Dr, Palo Alto, CA 94305
Phone
(650) 723-5272
Professional information
Howard Yuanhao Chang, Stanford CA
Specialties:
Dermatologist
Address:
269 Campus Dr, Stanford, CA 94305
Education:
Harvard Medical School - Doctor of Medicine
Stanford Hospital & Clinics - Residency - Dermatology
Stanford Hospital & Clinics - Residency - Dermatology
Board certifications:
American Board of Dermatology Certification in Dermatology
Howard Yuan-Hao Chang, Stanford CA
Specialties:
Dermatology
Work:
Stanford University
900 Blake Wilbur Dr, Stanford, CA 94305 Dermatology -North Campus
450 Broadway St, Redwood City, CA 94063 Stanford University
900 Blake Wilbur Dr, Palo Alto, CA 94304
900 Blake Wilbur Dr, Stanford, CA 94305 Dermatology -North Campus
450 Broadway St, Redwood City, CA 94063 Stanford University
900 Blake Wilbur Dr, Palo Alto, CA 94304
Education:
Harvard University(2000)
Diagnostic, Prognostic And Therapeutic Uses Of Long Non-Coding Rnas For Cancer And Regenerative Medicine
US Patent:
2014007, Mar 13, 2014
Filed:
Sep 7, 2013
Appl. No.:
14/020811
Inventors:
Howard Y. Chang - Stanford CA, US
David J. Wong - Palo Alto CA, US
Tiffany Hung - Palo Alto CA, US
David J. Wong - Palo Alto CA, US
Tiffany Hung - Palo Alto CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
C12Q 1/68
US Classification:
506 9, 435 612, 436501, 506 16
Abstract:
Long non-coding RNAs (lncRNAs) and methods of using them diagnostically and therapeutically for treatment of cancer, stem cell therapy, or regenerative medicine are disclosed. In particular, the invention relates to lncRNAs that that play roles in regulation of genes involved in cell proliferation, differentiation, and apoptosis. Such lncRNAs can be used as biomarkers to monitor cell proliferation and differentiation during cancer progression or tissue regeneration. One of the identified lncRNAs, referred to as PANDA (a P21-Associated NcRNA, DNA damage Activated), inhibits the expression of apoptotic genes normally activated by the transcription factor NF-YA. Inhibitors of PANDA sensitize cancerous cells to chemotherapy and can be used in combination with chemotherapeutic agents for treatment of cancer.
Diagnostic, Prognostic And Therapeutic Uses Of Long Non-Coding Rnas For Cancer And Regenerative Medicine
US Patent:
8557787, Oct 15, 2013
Filed:
May 11, 2012
Appl. No.:
13/470233
Inventors:
Howard Y. Chang - Stanford CA, US
David J. Wong - Palo Alto CA, US
Tiffany Hung - Palo Alto CA, US
David J. Wong - Palo Alto CA, US
Tiffany Hung - Palo Alto CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
C12N 15/11, A61K 38/00
US Classification:
514 44A, 514 194
Abstract:
Long non-coding RNAs (lncRNAs) and methods of using them diagnostically and therapeutically for treatment of cancer, stem cell therapy, or regenerative medicine are disclosed. In particular, the invention relates to lncRNAs that play roles in regulation of genes involved in cell proliferation, differentiation, and apoptosis. Such lncRNAs can be used as biomarkers to monitor cell proliferation and differentiation during cancer progression or tissue regeneration. One of the identified lncRNAs, referred to as PANDA (a P21-Associated NcRNA, DNA damage Activated), inhibits the expression of apoptotic genes normally activated by the transcription factor NF-YA. Inhibitors of PANDA sensitize cancerous cells to chemotherapy and can be used in combination with chemotherapeutic agents for treatment of cancer.
Methods Of Predicting Pairability And Secondary Structures Of Rna Molecules
US Patent:
2010027, Nov 4, 2010
Filed:
May 5, 2010
Appl. No.:
12/773977
Inventors:
Eran Segal - Rehovot, IL
Michael Kertesz - Rehovot, IL
Howard Y. Chang - Stanford CA, US
John Rinn - Boston MA, US
Adam Adler - Emerald Hills CA, US
Yue Wan - Stanford CA, US
Michael Kertesz - Rehovot, IL
Howard Y. Chang - Stanford CA, US
John Rinn - Boston MA, US
Adam Adler - Emerald Hills CA, US
Yue Wan - Stanford CA, US
Assignee:
Yeda Research And Development Co., Ltd. - Rehovot
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
C12Q 1/68, G01N 33/50
US Classification:
435 6, 436 94
Abstract:
Provided are methods of predicting a pairability of nucleotides of a plurality of RNA polynucleotides by (a) simultaneously determining a paired state or an unpaired state of nucleotides of the plurality of RNA polynucleotides; and (b) corresponding the paired state or the unpaired state of the nucleotides to a database of nucleic acid sequences, the database comprises nucleic acid sequences representing the plurality of RNA polynucleotides, thereby determining the pairability of nucleotides of the plurality of RNA polynucleotides. Also provided are methods of determining a secondary structure of a plurality of RNA molecules; methods of determining if a molecule is capable of modulating a secondary structure of at least one RNA polynucleotide of a plurality of RNA polynucleotides; and methods of screening for a marker associated with a pathology.
Methods For Constructing Association Maps Of Imaging Data And Biological Data
US Patent:
2010018, Jul 29, 2010
Filed:
Oct 30, 2007
Appl. No.:
12/447890
Inventors:
Howard Yuan-Hao Chang - Stanford CA, US
Eran Segal - Rehovot, IL
Michael Kuo - San Diego CA, US
Eran Segal - Rehovot, IL
Michael Kuo - San Diego CA, US
Assignee:
NATIONAL INSTITUTES OF HEALTH (NIH) U.S. DEPT OF HEALTH AND HUMAN SERVICES (DHHS). U.S. - BETHESDA
International Classification:
G06K 9/62
US Classification:
382128
Abstract:
A method for constructing an association map between imaging features and biological data is described. The method comprises combining one or more image features relating to a clinical subject with biological data and using an algorithm to make predictions based on the features and data.
Immunomodulation By Controlling Interferon-Gamma Levels With The Long Non-Coding Rna Nest
US Patent:
2014005, Feb 27, 2014
Filed:
Aug 23, 2013
Appl. No.:
13/974981
Inventors:
Michel Brahic - Stanford CA, US
J. Antonio Gomez - San Mateo CA, US
Howard Yuan-Hao Chang - Stanford CA, US
J. Antonio Gomez - San Mateo CA, US
Howard Yuan-Hao Chang - Stanford CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K 31/7105
US Classification:
4241841, 4242781
Abstract:
Compositions and methods of modulating an immune response by controlling levels of interferon-gamma (IFN-γ) production by leukocytes are disclosed. Adjustment of IFN-γ levels is achieved by increasing or decreasing the activity of NeST (nettoie pas Theiler's [cleanup not Theiler's]), a long non-coding RNA that induces expression of IFN-γ. In particular, the invention relates to the use of NeST and inhibitors of NeST to modulate levels of IFN-γ for treatment of inflammatory conditions, autoimmune diseases, infectious diseases, immunodeficiency, and cancer.
Rna Interactome Analysis
US Patent:
2013012, May 16, 2013
Filed:
Aug 7, 2012
Appl. No.:
13/569005
Inventors:
Howard Yuan-Hao Chang - Stanford CA, US
Ci Chu - Stanford CA, US
Ci Chu - Stanford CA, US
International Classification:
C12Q 1/68
US Classification:
506 9, 435 611
Abstract:
A method of sample analysis is provided. In certain cases, the method comprises: a) cross-linking the contents of a cell using a heat stable crosslinking agent to produce cross-linked ribonucleotide complexes; b) fragmenting the cross-linked ribonucleotide complexes to produce complexes comprising protein, RNA fragments and, optionally, genomic DNA fragments; c) contacting the complexes with a plurality of non-overlapping oligonucleotides comprise an affinity tag and that are complementary to a specific target RNA of the cell under high stringency conditions that include high temperature; d) isolating complexes that contain the oligonucleotides using the affinity tag to produce isolated complexes; e) enzymatically releasing the protein, RNA fragments and/or the genomic DNA fragments from the isolated complexes to produce a released component, without reversing the crosslinking; and f) analyzing the released component.
Linc Rnas In Cancer Diagnosis And Treatment
US Patent:
2012000, Jan 5, 2012
Filed:
Jun 17, 2011
Appl. No.:
13/163228
Inventors:
Howard Y. Chang - Stanford CA, US
Rajnish A. Gupta - Sunnyvale CA, US
Rajnish A. Gupta - Sunnyvale CA, US
Assignee:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY - PALO ALTO CA
International Classification:
A61K 31/7088, A61K 31/7105, C40B 30/04, A61P 35/00, C12Q 1/68, C40B 60/12, C12M 1/34, A61P 35/04, A61K 31/713, C12N 5/09
US Classification:
514 44 A, 506 9, 435375, 435 612, 435 611, 506 39, 4352872
Abstract:
Long non-coding RNAs (lincRNAs), a relatively recently recognized class of widely transcribed genes, are thought to affect chromatin state and epigenetic regulation, but their mechanisms of action and potential roles in human disease are poorly understood. The present invention shows that long non-coding RNAs in the human HOX loci are systematically dysregulated during breast cancer progression, and that expression levels of the lincRNA termed HOTAIR can predict cancer metastasis. Elevated levels of HOTAIR can lead to altered patterns of Polycomb binding to the genome. These findings indicate that lincRNAs have active roles in modulating the cancer epigenome and may be important targets for cancer diagnosis and therapy.
Profiling For Determination Of Response To Treatment For Inflammatory Disease
US Patent:
2010020, Aug 12, 2010
Filed:
Jan 27, 2010
Appl. No.:
12/694980
Inventors:
Howard Yuan-Hao Chang - Stanford CA, US
William H. Robinson - Palo Alto CA, US
David Fiorentino - Stanford CA, US
Lorinda Chung - Stanford CA, US
Adam Adler - Emerald Hills CA, US
William H. Robinson - Palo Alto CA, US
David Fiorentino - Stanford CA, US
Lorinda Chung - Stanford CA, US
Adam Adler - Emerald Hills CA, US
International Classification:
C40B 30/04, C12Q 1/68, C40B 40/06, C07H 21/00
US Classification:
506 9, 435 6, 506 16, 536 2433, 536 243
Abstract:
The present invention relates to compositions and methods for treating, characterizing, and diagnosing autoimmune diseases or other inflammatory diseases. In particular, the present invention provides gene expression profiles as well as novel TKI Responsive Signature(s) useful for the diagnosis, characterization, prognosis and treatment of autoimmune disease or other inflammatory diseases.